77 related articles for article (PubMed ID: 7472776)
1. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression.
Martinez JC; Mateo M; Sánchez-Beato M; Villuendas R; Orradre JL; Algara P; Sánchez-Verde L; García P; López C; Martínez P
J Pathol; 1995 Sep; 177(1):27-34. PubMed ID: 7472776
[TBL] [Abstract][Full Text] [Related]
2. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas.
Finnegan MC; Goepel JR; Royds J; Hancock BW; Goyns MH
Cancer Lett; 1994 Nov; 86(2):215-21. PubMed ID: 7982210
[TBL] [Abstract][Full Text] [Related]
5. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53, MDM2, p21waf1, bcl-2, and retinoblastoma gene proteins in myelodysplastic syndrome after autologous bone marrow transplantation for lymphoma.
Brynes RK; Wilson CS; Kim AB; McCourty A
Mod Pathol; 1997 Nov; 10(11):1120-7. PubMed ID: 9388063
[TBL] [Abstract][Full Text] [Related]
7. P53 protein expression in lymphomas and reactive lymphoid tissue.
Villuendas R; Piris MA; Orradre JL; Mollejo M; Algara P; Sanchez L; Martinez JC; Martinez P
J Pathol; 1992 Mar; 166(3):235-41. PubMed ID: 1381424
[TBL] [Abstract][Full Text] [Related]
8. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virus.
Tzardi M; Kouvidou C; Panayiotides I; Koutsoubi K; Stefanaki K; Giannikaki E; Darivianaki K; Zois M; Eliopoulos G; Kakolyris S; Delides G; Rontogianni D; Kanavaros P
Anticancer Res; 1996; 16(5A):2813-9. PubMed ID: 8917390
[TBL] [Abstract][Full Text] [Related]
10. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
12. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
13. p53, Rb and bcl-2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections.
Mateo MS; Sanchez-Beato M; Martinez JC; Orfao A; Orradre JL; Piris MA
J Clin Pathol; 1995 Feb; 48(2):151-9. PubMed ID: 7745116
[TBL] [Abstract][Full Text] [Related]
14. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue.
Wołowiec D; Benchaib M; Pernas P; Deviller P; Souchier C; Rimokh R; Felman P; Bryon PA; Ffrench M
Leukemia; 1995 Aug; 9(8):1382-8. PubMed ID: 7643628
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of p53 and MDM2 proteins in hematological malignancies.
Koníková E; Kusenda J
Neoplasma; 2003; 50(1):31-40. PubMed ID: 12687276
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease.
Foss HD; Araujo I; Demel G; Klotzbach H; Hummel M; Stein H
J Pathol; 1997 Sep; 183(1):44-50. PubMed ID: 9370946
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease.
Chilosi M; Doglioni C; Menestrina F; Montagna L; Rigo A; Lestani M; Barbareschi M; Scarpa A; Mariuzzi GM; Pizzolo G
Blood; 1994 Dec; 84(12):4295-300. PubMed ID: 7994045
[TBL] [Abstract][Full Text] [Related]
18. Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease.
Hsu PL; Hsu SM
Cancer Res; 1998 Dec; 58(23):5507-13. PubMed ID: 9850087
[TBL] [Abstract][Full Text] [Related]
19. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
20. p53 expression in lymphatic malignancies.
Soini Y; Pääkkö P; Alavaikko M; Vähäkangas K
J Clin Pathol; 1992 Nov; 45(11):1011-4. PubMed ID: 1452775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
